ArticlePatient preference and adherence2016
Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.
Article in Patient preference and adherence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Shared decision-making interventions for people with mental health conditions.The Cochrane database of systematic reviews · 2022Pooled it
- Comparison of Side Effects Between 3-Monthly and 1-Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia.Human psychopharmacology · 2026Article
- Matched Comparison Examining the Effect of Obesity on Clinical, Economic, and Humanistic Outcomes in Patients with Bipolar I Disorder.Advances in therapy · 2024Article
- Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder.BMC psychiatry · 2024Article
- Factors Influencing Patient and Caregiver Preferences for Antipsychotic Treatment of Schizophrenia in China: A Discrete Choice Experiment.Patient preference and adherence · 2023Article
- The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States.AIDS research and therapy · 2022Article
- Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections.Neuropsychiatric disease and treatment · 2022Article
- Computerized Conjoint Analysis of the Weight Treatment Preferences of Individuals With Schizophrenia.Psychiatric services (Washington, D.C.) · 2021Article
- Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Article
- Benefit-risk evaluation: the past, present and future.Therapeutic advances in drug safety · 2019Review
- Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia.Neuropsychiatric disease and treatment · 2019Review
- Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice.Neuropsychiatric disease and treatment · 2019Review
- Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists · 2018Article
- Symposium Title: Preference Evidence for Regulatory Decisions.The patient · 2018Article
- Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling.Patient preference and adherence · 2018Article
- Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.Neuropsychiatric disease and treatment · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo quantify clinical trial participants' and investigators' judgments with respect to the relative importance of efficacy and safety attributes of antipsychotic treatments for schizophrenia, and to assess the impact of formulation and adherence.
methodsDiscrete-choice experiment surveys were completed by patients with schizophrenia and physician investigators participating in two phase-3 clinical trials of paliperidone palmitate 3-month long-acting injectable (LAI) antipsychotic. Respondents were asked to choose between hypothetical antipsychotic profiles defined by efficacy, safety, and mode of administration. Data were analyzed using random-parameters logit and probit models.
resultsPatients (N=214) and physicians (N=438) preferred complete improvement in positive symptoms (severe to none) as the most important attribute, compared with improvement in any other attribute studied. Both respondents preferred 3-month and 1-month injectables to oral formulation (
conclusionImprovement in positive symptoms was the most important attribute. Patients and physicians preferred LAIs over oral antipsychotics, with physicians showing a greater preference for 3-month over 1-month LAI. Physicians and patients were willing to accept reduced efficacy in exchange for switching a patient from an oral formulation to a LAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.